Preoperative chemotherapy or chemoradiation followed by surgery have improved survival outcomes and the likelihood of margin-negative esophagogastrectomy in patients with locoregional esophageal adenocarcinoma (EAC).¹ However, these patients’ 5-year survival rates remain low.^2,3 Biomarker-driven targeted therapies have had limited success in EAC patients, primarily in less than 20% of those with stage IV human epidermal growth factor receptor 2 (Her2-neu)-overexpressing disease who receive trastuzumab.^4–6 To date, no targeted agent has demonstrated benefit as an adjunct to 5-fluorouracil-based chemotherapy or chemoradiation in patients with locally advanced EAC.

中文翻译：

---

通过一种新的 CDK9/p-TEFb 抑制剂靶向 CDK9 和 MCL-1，联合或不联合 5-氟尿嘧啶治疗食管腺癌。

术前化疗或放化疗后手术改善了局部区域食管腺癌 (EAC) 患者的生存结果和切缘阴性食管胃切除术的可能性。¹然而，这些患者的 5 年生存率仍然很低。^2,3生物标志物驱动的靶向治疗在 EAC 患者中取得的成功有限，主要是在接受曲妥珠单抗治疗的 IV 期人类表皮生长因子受体 2 (Her2-neu) 过度表达疾病患者中不到 20%。^4-6迄今为止，尚无靶向药物作为 5-氟尿嘧啶为基础的化疗或放化疗的辅助手段对局部晚期 EAC 患者有益。